Comparative Pharmacology
Head-to-head clinical analysis: MONISTAT versus NYSERT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONISTAT versus NYSERT.
MONISTAT vs NYSERT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miconazole, the active ingredient in MONISTAT, inhibits fungal CYP51 (lanosterol 14-alpha-demethylase), blocking ergosterol synthesis and disrupting fungal cell membrane integrity, leading to cell death.
NYSERT is a fixed-dose combination of nystatin and sertaconazole. Nystatin, a polyene antifungal, binds to ergosterol in fungal cell membranes, disrupting permeability and causing cell death. Sertaconazole, an azole antifungal, inhibits lanosterol 14α-demethylase (CYP51), blocking ergosterol synthesis and accumulation of toxic methylsterols. Synergistic action provides broad-spectrum antifungal activity against Candida spp. and dermatophytes.
Intravaginal: 200 mg suppository at bedtime for 3 days, or 100 mg suppository at bedtime for 7 days, or 2% cream 5 g intravaginally at bedtime for 7 days. Topical: Apply 2% cream twice daily for 2-4 weeks.
10 mg orally once daily at bedtime, with or without food.
None Documented
None Documented
Approximately 90-120 minutes; supports twice-daily local dosing.
Terminal elimination half-life approximately 20-25 hours in healthy adults; prolonged in hepatic impairment (up to 40 hours) and in elderly patients.
Primarily fecal (approximately 90%) as unchanged drug; less than 2% renal elimination.
Primarily hepatic metabolism (CYP3A4) followed by biliary excretion of metabolites; ~60% fecal, ~30% renal (as metabolites), <5% unchanged in urine.
Category C
Category C
Antifungal
Antifungal